Aspen Investment Management Inc Grows Position in Bristol Myers Squibb Company $BMY

Aspen Investment Management Inc raised its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 123.1% in the 1st quarter, HoldingsChannel.com reports. The firm owned 23,789 shares of the biopharmaceutical company’s stock after purchasing an additional 13,125 shares during the quarter. Aspen Investment Management Inc’s holdings in Bristol Myers Squibb were worth $1,443,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of BMY. Swiss RE Ltd. purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at $25,000. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth $25,000. Physician Wealth Advisors Inc. raised its position in shares of Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the period. Bayban acquired a new position in Bristol Myers Squibb in the fourth quarter valued at $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb in the fourth quarter valued at $32,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the subject of several research analyst reports. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Cantor Fitzgerald lifted their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, April 8th. HSBC boosted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Guggenheim reissued a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Finally, UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and an average target price of $61.31.

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Up 0.2%

Shares of Bristol Myers Squibb stock opened at $54.10 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The stock has a market cap of $110.48 billion, a price-to-earnings ratio of 15.20, a price-to-earnings-growth ratio of 0.15 and a beta of 0.24. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company has a fifty day moving average price of $57.34 and a 200 day moving average price of $57.09.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the company posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.7%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.